Results 31 to 40 of about 38,364 (253)

Cannabis use and depression: a longitudinal study of a national cohort of Swedish conscripts

BMC Psychiatry, 2012
Background While there is increasing evidence on the association between cannabis use and psychotic outcomes, it is still unclear whether this also applies to depression.
Manrique-Garcia Edison, Zammit Stanley, Dalman Christina, Hemmingsson Tomas, Allebeck Peter   +4 more
doaj   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Prevalence and correlates of non-daily and daily cannabis use among persons 15 years and older in South Africa: results of a national survey in 2017

Substance Abuse Treatment, Prevention, and Policy, 2021
Background The study aimed to assess the prevalence and correlates of non-daily and daily cannabis use among persons 15 years and older in South Africa.
Shandir Ramlagan, Karl Peltzer, Supa Pengpid   +2 more
doaj   +1 more source

Pharmacotherapies for cannabis use disorder

Cochrane Database of Systematic Reviews
Globally, cannabis use is prevalent and widespread. There are currently no pharmacotherapies approved for the treatment of cannabis use disorder (a problematic pattern of cannabis use that leads to clinically significant impairment or distress). This is the second update of a Cochrane Review first published in the Cochrane Library in Issue 12, 2014.To ...
Francesca Spiga, Thomas Parkhouse, Victor M. Tang, Jelena Savović, Bernard Le Foll, Suzanne Nielsen   +5 more
openaire   +3 more sources

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

Schizoaffective disorder induced by substance abuse: a case report

European Psychiatry, 2022
Introduction We present the case of a 33-year old man that suffer chronic cocaine and cannabis use since adolescence and at age of 25 develops depressive symptoms and later psychotic symptoms not congruent with mood state.
A. García Carpintero, B. Rodado León, A. Bermejo Pastor, M. Jiménez Cabañas, T. Ponte López   +4 more
doaj   +1 more source

Breaking point: Identifying the factors that predict suspension from school

British Educational Research Journal, EarlyView.
Abstract School suspensions are associated with adverse educational and psychosocial outcomes, yet little is known about how structural disadvantage, relational factors, health behaviours, well‐being indicators and school‐level factors jointly predict suspension risk in England.
Stephanie Cahill, Roberto Vagnetti, Christopher Knowles, Emma Thornton, Qiqi Cheng, Neil Humphrey   +5 more
wiley   +1 more source

Cannabis Use Disorder

Nimmana BK, Aslam SP, Marwaha R.
europepmc   +4 more sources

Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Treatment Adherence

Frontiers in Psychiatry, 2018
Background: Previous literature suggests that prevalence of cannabis use in the early phase of psychosis is high, and that early psychosis patients are at high-risk for violent behavior.
Valerie Moulin, Philipp Baumann, Mehdi Gholamrezaee, Luis Alameda, Luis Alameda, Julie Palix, Jacques Gasser, Philippe Conus   +7 more
doaj   +1 more source